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Abstract
Between the 17th and 20th centuries, blood was transfused from various animal species into 
patients with a variety of pathological conditions. Skin grafts were carried out in the 19th century, 
with grafts from a variety of animals, with frogs being the most popular. In the 1920s, Voronoff 
advocated the transplantation of slices of chimpanzee testis into elderly men, believing that the 
hormones produced by the testis would rejuvenate his patients. In 1963–4, when human organs 
were not available and dialysis was not yet in use, Reemtsma transplanted chimpanzee kidneys 
into 13 patients, one of whom returned to work for almost 9 months before suddenly dying from 
what was believed to be an electrolyte disturbance. The first heart transplant in a human ever 
performed was by Hardy in 1964, using a chimpanzee heart, but the patient died within two hours. 
Starzl carried out the first chimpanzee-to-human liver transplantation in 1966; in 1992 he obtained 
patient survival for 70 days following a baboon liver transplant. The first clinical pig islet 
transplant was carried out by Groth in 1993. Today, genetically-modified pigs offer hope of a 
limitless supply of organs and cells for those in need of a transplant.
The concept of xenotransplantation (cross-species transplantation) is not new, and there 
have been numerous clinical attempts during the past 300 years or more [1–3].
Mythology
A review of Greek mythology and of religious tracts—particularly, for example, from the 
Hindu religion—draws attention to the fact that humans have been interested in the 
possibility of merging physical features from various animal species for hundreds of years. 
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For example, the lamassu has been selected as the mythological figure to represent the 
International Xenotransplantation Association and its official scientific journal, 
Xenotransplantation.
The late Keith Reemtsma pointed out that possibly one of the earliest examples of 
xenotransplantation was the attempt by Daedalus and his son, Icarus, to fly across the sea 
from Crete to mainland Greece with the help of bird wings attached to their arms [4]. Icarus 
failed in the attempt, but Daedalus made the journey successfully.
Blood xenotransfusion
If we look beyond the realm of mythology and legend, we come to the 17th century, when 
Jean Baptiste Denis began the clinical practice of blood transfusion from animals to humans 
[5]. Perhaps not surprisingly, the results were mixed. As a result, xenotransfusion was 
banned in France for a number of years.
Skin xenotransplantation
In the 19th century, skin grafts became relatively popular between various animal species 
and humans [6, 7]. The grafts were either free or pedicle grafts. Pedicle grafts were 
complicated because they required the donor, e.g., a sheep, to be strapped immobile to the 
patient for several days, during which time the graft would reputedly be vascularized by the 
recipient. If this occurred, the graft could be disconnected from the donor. It is almost 
certain that none of these grafts was in any way successful, although some “successes” were 
reported.
The fact that many of the species used as donors—sheep, rabbits, dogs, cats, rats, chickens, 
and pigeons—had hair, feathers, or fur growing from the skin did not appear to disconcert 
the surgeons involved, but the trend was to use animal species in which these accoutrements 
were not present. The ideal graft would appear to have been from frogs, which were 
sometimes “skinned alive.” It is possible that some of these grafts were “successful” in that, 
when used to cover a skin ulcer, they provided protection, at least for a number of days, 
while the ulcer healed beneath the graft. However, probably none of the grafts actually 
became permanent.
Corneal xenotransplantation
Remarkably, in 1838 the first corneal xenotransplantation (from a pig) was performed in a 
patient, whereas the first corneal allotransplantation (human-to-human) was not carried out 
until more than 65 years later, in 1905. The field of corneal xenotransplantation has been 
reviewed by Hara and Cooper [8, 9].
The surgery of blood vessel anastomosis
More scientific efforts had to wait until the 20th century, when the French experimental 
surgeon, Alexis Carrel, working first in France and subsequently in North America, 
developed surgical techniques for anastomosing blood vessels, which enabled organ 
transplantation to be carried out successfully for the first time. For this work he was awarded 
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the Nobel Prize in 1912. He developed an interest in cross-species transplantation from an 
experimental perspective.
“Rejuvenation” by cell xenotransplantation
A few years later, Serge Voronoff, a Russian émigré working in Paris, developed the 
concept of transplanting cells that produced a hormone in which the recipient was deficient. 
This is another example of a visionary scientist who was ahead of his time. Today we are 
doing exactly what he envisaged, namely transplanting human pancreatic islets that produce 
insulin in patients with severe type 1 diabetes. In view of the limited number of human 
pancreases that become available each year, there is a growing interest in using pig islets for 
this purpose.
Voronoff’s main interest, however, was in reversing the effects of aging in elderly men who 
had lost their “zest for life.” He carried out a significant number of chimpanzee or baboon 
testicular transplants in male human recipients [10]. His technique was to slice up the animal 
testicle and insert the slices into the recipient’s testicle. The procedure became popular on 
both sides of the Atlantic, and several hundred of these operations were performed. It is 
inconceivable that any of them had any beneficial effect whatsoever, except psychological, 
but there were reports of remarkable “rejuvenation” of men who reported much increased 
energy after the operation. Surprisingly, reports of complications appear to have been 
uncommon.
The concept of transplanting glandular tissue to produce hormones that would benefit the 
recipient was continued in the United States by a much less scientific doctor, John Brinkley, 
whose work was carried out largely in Kansas and Texas [11]. His chosen donor was the 
goat, as he had been convinced by a local farmer of its sexual potency.
Kidney xenotransplantation
By the 1960s, Keith Reemtsma (Figure 1)—at that time at Tulane University in Louisiana—
hypothesized that nonhuman primate kidneys might function in human recipients and thus 
be a successful treatment for renal failure. At that time, the concept of kidney transplantation 
had been established largely by French and American surgeons, but the availability of 
kidneys from deceased humans was extremely limited and chronic dialysis was not yet being 
undertaken. In Reemtsma’s opinion, therefore, there was little alternative to death for the 
patient unless organs could be made available from nonhuman species. He selected the 
chimpanzee as the source of organs because of its close evolutionary relationship to humans. 
He carried out 13 of these transplants, on each occasion transplanting both kidneys from a 
chimpanzee (that generally weighs significantly less than an adult human) into the recipient 
[12].
Most of the transplants failed within 4 to 8 weeks, either from rejection (because of the 
limited immunosuppressive agents available at the time) or from an infectious complication 
(because of the overadministration of these agents). Nevertheless, one of Reemtsma’s 
patients lived for 9 months, returning to work as a schoolteacher and evidently remaining in 
good health until she suddenly collapsed and died. At autopsy, the chimpanzee kidneys 
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appeared normal and showed no signs of acute or chronic rejection. It was suggested that 
she had died from an acute electrolyte disturbance. This is possible since the transplantation 
of nonhuman primate kidneys into patients was frequently associated with an immense 
diuresis in the early posttransplantation period, often exceeding 20 liters in 24 hours, and so 
there possibly could have also been a late electrolyte imbalance.
The concept of using nonhuman primates as kidney donors was expanded by several 
surgeons, particularly by Tom Starzl (Figure 2) in Colorado, who used baboons as donors 
[13]; his results were similar to those of Reemtsma, except that he did not achieve any 
relatively long-term survivors. Others in the US and in France also had small experiences 
[2].
Heart xenotransplantation
James Hardy (Figure 3), who had carried out the first human lung allotransplant in 1963, 
visited Reemtsma and was impressed by the health of some of the patients with chimpanzee 
kidney transplants. In 1964, Hardy was determined to carry out the first clinical heart 
transplantation and decided to acquire some chimpanzees as potential “donors” in case he 
could not identify a deceased human donor. He had a less-than-ideal patient who would not 
be accepted for heart transplantation today, as he had widespread atheromatous vascular 
disease throughout his body—for which he had undergone amputations of both legs—and 
was in a semicomatose state at the time the transplant was undertaken. However, as the 
patient was rapidly dying, Hardy was stimulated to transplant a chimpanzee heart [14]. The 
heart proved not to be large enough to support the circulation and failed within a couple of 
hours.
In contrast to the response to the attempted lung allotransplantation, the public and medical 
professional response to the heart xenotransplantation was adverse and dissuaded Hardy and 
his colleagues from carrying out any further attempts. The procedure of cardiac 
allotransplantation was later established by Barnard and his colleagues in 1967 [15], who 
later also carried out two heterotopic cardiac xenotransplants, using a chimpanzee and a 
baboon as ‘donors [16].
It is of interest to note that the consent form for Hardy’s operation—which, in view of the 
patient’s semicomatose condition, was signed by a close relative—stipulated that no heart 
transplant had ever been performed, but made no mention of the fact that an animal heart 
might be used for the procedure. Such was the medicolegal situation at that time that this 
“informed” consent was not considered in any way inadequate.
Perhaps the best known clinical cardiac xenotransplantation since Hardy’s attempt was that 
by Leonard Bailey (Figure 4), who transplanted a baboon heart into an infant girl, known as 
Baby Faye, in 1983. At that time, it was almost impossible to obtain human organs from 
infants, particularly those with anencephaly, for transplantation into infants with life-
threatening congenital heart disease. The surgical procedure in Baby Faye was technically 
successful, but the graft underwent acute rejection and the patient died 20 days later [17]. As 
the graft was necessarily taken from a baboon that was ABO-incompatible with the recipient
—as the O blood type is essentially not found in baboons—this might have added to the 
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severity of rejection. Even though cyclosporine had become available by this time, the 
immunosuppressive therapy was not sufficient to prevent xenograft rejection.
This procedure did little to advance progress in xenotransplantation, but it did draw public 
and medical attention to the dearth of deceased human organs available for infants in need of 
a transplant. Following the procedure, particularly with the immense publicity associated 
with it, the situation with regard to donation of organs from infants became very much 
improved, and Bailey went on to develop an extremely successful cardiac 
allotransplantation program in infants and children at Loma Linda University.
Liver xenotransplantation
Tom Starzl (Figure 2), who is one of the greatest pioneers in the field of kidney and liver 
allotransplantation, performed a handful of liver transplants between nonhuman primates 
and young patients in Colorado in the 1960s without lasting success [18–21]. When the 
addition of tacrolimus had improved the immunosuppressive armamentarium, he and his 
team in Pittsburgh performed two liver transplants from baboons in adult patients in the 
1990s, with one patient surviving for 70 days [22]. The results, however, were not 
successful enough to warrant continuing this experimental clinical trial.
Most of the early attempts at clinical organ xenotransplantation used nonhuman primate 
species as sources of the organ, although there were a few attempts using the pig [23] and 
other nonprimate mammals, but without significant success [2].
Islet xenotransplantation
A Swedish group headed by Carl Groth (Figure 5) was the first to attempt pig islet 
transplantation in patients with diabetes in 1993 [24]. Although porcine C-peptide was 
documented in the blood of some of the patients, indicating that some islets survived, no 
clinical benefit was obtained.
Xenotransplantation using pigs as sources of organs and cells
The advantages of xenotransplantation, particularly if we could use a readily available 
animal source, such as the pig, would be numerous (Table 1) [25]. There would be an 
unlimited supply of “donor” organs, which would resolve the current increasing and severe 
shortage of human organs. The immunological and pathobiological problems associated 
with pig xenotransplantation, however, are significant and probably reflect the fact that it 
has been 80 million years since the pig and human diverged on the evolutionary scale. 
Therefore, in the words of Claus Hammer, what we are trying to do is to “outwit evolution.” 
The pathobiological barriers associated with pig-to-primate organ and cell transplantation 
are summarized elsewhere in this issue.
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Highlights
• Clinical xenotransplantation has involved skin, corneas, and blood
• Nonhuman primate kidney and heart grafts were transplanted into patients
• The first clinical attempt at pig islet transplantation was in 1993
• There are advantages in the use of the pig as the source of organs and cells
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Figure 1. 
Keith Reemtsma (1925–2000). [Courtesy the late Keith Reemtsma.]
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Figure 2. 
Tom Starzl (born 1926). [Courtesy Thomas E. Starzl.]
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Figure 3. 
James Hardy (1918–2003). [Courtesy the late James Hardy.]
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Figure 4. 
Leonard Bailey (born 1942). [Courtesy Leonard Bailey.]
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Figure 5. 
Carl-Gustav Groth (1933–2014). [Courtesy the late Carl-Gustav Groth.]
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Table 1
The advantages and disadvantages of the pig vs baboon as a epotential source of organs and cells for humans
Pig Baboon
Availability Unlimited Limited
Breeding potential Good Poor
Period to reproductive maturity 4–8 months 3–5 years
Length of pregnancy 114 ± 2 days 173–193 days
Number of offspring 5–12 1–2
Growth Rapid (adult human size within 6 months)* Slow (9 years to reach maximum size)
Size of adult organs Adequate Inadequate†
Cost of maintenance Significantly lower High
Anatomical similarity to humans Moderately close Close
Physiological similarity to humans Moderately close Close
Relationship of immune system to humans Distant Close
Knowledge of tissue typing Considerable (in selected herds) Limited
Necessity for blood type compatibility with humans Probably unimportant Important
Experience with genetic engineering Considerable None
Risk of transfer of infection (xenozoonosis) Low High
Availability of specific pathogen- free animals Yes No
Public opinion More in favor Mixed
*
Breeds of miniature swine are approximately 50% of the weight of domestic pigs at birth and sexual maturity and reach a maximum weight of 
approximately 30% of standard breeds. At full size, miniature swine are easier to house and to handle. Furthermore, inbred herds are available, 
though cloning of any pig can result in inbred herds, if needed. Although MHC-identical miniature swine may have some specific immunologic 
advantage, the disadvantage is that they cannot be cross-bred with other pig strains in which a genetic modification has been introduced; if cross-
breeding is carried out, clearly MHC identity is lost. (Reproduced with permission from Cooper DKC. A brief history of cross-species organ 
transplantation. Baylor Univ Med Center Proc 2012;25:49–57)
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